Aspira Womens HealthAWHL +3.89%36 Gross Margin % is 54.45% as of Mar. 2026, which is 52% above its 10-year median of 35.76. GuruFocus rates AWHL with a GF Score™ of 36/100 and a GF Value™ of $0.28 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Aspira Womens Health ranks better than 62.37% on this metric.
The historical rank and industry rank for Aspira Womens Health's Gross Margin % or its related term are showing as below:
AWHL'
s Gross Margin % Range Over the Past 10 Years
Min: -2.92 Med: 35.76 Max: 64.18
Current: 60.94
During the past 13 years, the highestGross Margin % of Aspira Womens Health was 64.18%. The lowest was -2.92%. And the median was 35.76%.
AWHL's Gross Margin % is ranked better than 62.37% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.45
vs AWHL: 60.94
Aspira Womens Health had a gross margin of 54.45% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Aspira Womens Health was 16.50% per year.
Aspira Womens Health (OTCPK:AWHL) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Aspira Womens Health had a gross margin of 54.45% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Aspira Womens Health Gross Margin % Related Terms
Aspira Womens Health Gross Margin % Historical Data
* Premium members only.
The historical data trend for Aspira Womens Health's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AWHL vs BIOQ, MBAI, XWEL: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Aspira Womens Health's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Aspira Womens Health (AWHL) has a Gross Margin % of 54.45% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Aspira Womens Health and its competitors. This is 52% above median its historical median of 35.76. According to the industry distribution chart, Aspira Womens Health ranks #73 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 37.6%.
Is Aspira Womens Health's Gross Margin % too high?
Aspira Womens Health's current Gross Margin % of 54.45% is 52% above median its 10-year median of 35.76. The Medical Diagnostics & Research industry median Gross Margin % is 50.45. Aspira Womens Health's value of 54.45% is 7.9% above this industry median. Based on the distribution chart, Aspira Womens Health ranks #73 out of 194 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Aspira Womens Health has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Womens Health's Gross Margin % compare to BIOQ and MBAI?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Womens Health ranks #73 out of 194 companies for Gross Margin %. This puts Aspira Womens Health in the upper half of its industry. The industry median Gross Margin % is 50.45. Aspira Womens Health's value of 54.45% is 7.9% above this benchmark. While the company's 10-year median is 35.76 vs. the industry median of 50.45, Aspira Womens Health has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.45, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspira Womens Health's current Gross Margin % of 54.45% is 7.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Aspira Womens Health and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspira Womens Health's current Gross Margin % is 54.45%, which is 52% above median its own 10-year median of 35.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Womens Health stock overvalued right now?
Based on GuruFocus' analysis, Aspira Womens Health (AWHL) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $0.44 — trading 57.7% above its estimated fair value. The current Gross Margin % is 54.45%, which is 52% above median its 10-year median of 35.76 and 7.9% above the Medical Diagnostics & Research industry median of 50.45. Aspira Womens Health's overall GF Score™ is 36/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Aspira Womens Health (AWHL), the current Gross Margin % is 54.45% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Womens Health (AWHL) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued.
The current stock price of $0.44 is trading 57.7% above its estimated GF Value™ of $0.28.
GuruFocus considers Aspira Womens Health to be Significantly Overvalued.
Key valuation signals for AWHL:
Gross Margin %: 54.45% (52% above median its 10-year median of 35.76)
GF Value™: $0.28 vs. price of $0.44 (57.7% above fair value)
Industry Position: 7.9% above the Medical Diagnostics & Research median (#73 of 194)
No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.
36GF Score
Get the complete analysis for AWHL
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AWHL has been successfully added to your 
